PBS-80
The commercial-scale manufacturing bioreactor for allogeneic cell therapy production at scale. built on the same Vertical-Wheel® Technology validated at every previous scale.

Why PBS-80
The PBS-80 extends proven processes to commercial production volumes while preserving the culture environment your cells have been thriving in. It is designed to help manufacturers increase output, support growing demand, and maintain process consistency across the product lifecycle.
Manufacture large cell therapy batches at production-relevant volumes.
Standardize large-scale manufacturing with recipes, process control, alarms, and comprehensive data capture.
Designed for commercial manufacturing with single-use, cGMP-ready vessels and secure, audit-ready, 21 CFR Part 11-compliant software and IQ/OQ documentation.
Support high-density, high-yield production using external perfusion systems and closed-system manufacturing workflows.
The PBS-80 Vertical-Wheel FLUIDIX™ Vessel
The PBS-80 runs pre-sterilized, single-use Vertical-Wheel FLUIDIX™ 80L Vessels for commercial-scale manufacturing to meet the market demand of your therapy.

Proven With PBS-80
Published Vertical-Wheel data at this scale — protocols, app. notes, peer-reviewed papers, case studies, posters, webinars, etc.
This poster, presented at ISSCR Kyoto 2026, demonstrates a scalable strategy for iPSC manufacturing using Vertical-Wheel Bioreactors, addressing expansion, process development, cell banking, and differentiation. Linear scale-up from PBS-0.1 through PBS-80 produced 200 billion iPSCs at a 50 L working volume while maintaining pluripotency and normal karyotype. High-density work cell banks were developed through 3D adaptation and retained differentiation potential toward cardiomyocytes and pancreatic progenitors. MiniPRO further served as a controlled scale-down model, demonstrating growth…
This presentation, presented at ISSCR Kyoto 2026 explores how Vertical-Wheel Bioreactors can reduce development and manufacturing risk for PSC therapies by providing a scalable platform from process development through commercial production. It highlights global clinical trials supported by Vertical-Wheel technology, predictive scale-down with MiniPRO, controlled hydrodynamics, automation, and linear scale-up through PBS-80. Data demonstrate consistent PSC growth across scales, culminating in greater than 200 billion cells from a 50 L batch while maintaining pluripotency, illustrating a…
This guide collects and summarizes process parameters from successful experiments performed in Vertical-Wheel® bioreactors, across a variety of cell types including pluripotent stem cells, mesenchymal stem/stromal cells, exosomes and extracellular vesicles, organoids, and immune cells. Find the publication or resource most relevant to your own experiment to help with your process development.
This poster describes linear scale-up of human induced pluripotent stem cell aggregate expansion across 0.1, 3, 15, and 80 L Vertical-Wheel bioreactors. A baseline small-scale process was used to establish operating conditions and assess reproducibility and robustness across media, operators, cell lines, and agitation rates. Perfusion-based media exchange was introduced at reactor scales of 3 L and above to address increasing settlement times and aggregate merging as vessel scale increased. Cell growth, aggregate size, metabolic consumption and production, and pluripotency markers were…
This poster presents a three-dimensional process for linear scale-up of human induced pluripotent stem cell expansion from 0.1 to 80 L in Vertical-Wheel® Bioreactors. Cultures maintained growth, aggregate sphericity, pluripotency, karyotype, and functional pluripotency across scales. Serial aggregate culture and scalable harvest, concentration, and cryopreservation generated high-density working cell banks that retained viability, growth, genomic stability, and differentiation competence after thaw. The banks supported shortened endocrine, islet-like, and cardiomyocyte workflows through…
This white paper examines the economic and operational advantages of Vertical-Wheel® Bioreactors compared with planar culture and conventional stirred-tank systems for cell therapy manufacturing. Key cost drivers include expansion efficiency, labor, facility footprint, process scalability, batch reproducibility, and product quality. Published examples demonstrate increased cell yield, fewer processing steps, reduced labor, and improved facility utilization through single-use, closed-system operation. Low-shear, homogeneous hydrodynamics support consistent growth and critical quality…
PBS-80 Parts - (selected parts are added to cart for quote requests)
Loading part numbers…
We Support You Every Step of the Way
Our application scientists help you get the most out of PBS-80, and help you plan for the steps that come next.
Our application scientists optimize cell yield and quality on PBS-80 with you.
Equivalent set points from PBS-80 to commercial scale, CFD-validated at every step.
Guided-optimization packages that move you from R&D to clinical scale.
Go Vertical, Today
Tell us what you need and we’ll take it from there.